Impacts of muscle mass dynamics on prognosis of outpatients with cirrhosis
1
조회
0
다운로드
5
인용
0
참고문헌
키워드
초록
Background/Aims: Sarcopenia negatively affects the prognosis of cirrhotic patients, but clinical implications of changes in muscle mass remain unclear. We aimed to elucidate its role in the prognosis of outpatients with cirrhosis. Methods: Patients with cirrhosis who underwent annual abdominal computed tomography (CT) for hepatocellular carcinoma surveillance were included in the prospective cohort. The L3 skeletal muscle index (SMI) was adopted as a proxy for the amount of skeletal muscle, and the rate of SMI change between inclusion and after 1 year (ΔSMI/yr%) was calculated. Results: In total, 595 patients underwent a second CT after 1 year. Among them, 109 and 64 patients had sarcopenia and Child-Pugh class B/C decompensation at inclusion, which changed to 103 and 45 at the 1-year follow-up, respectively. During a median follow-up of 30.1 months after 1 year, 86 patients had at least one cirrhosis complication, and 18 died or received liver transplantation. In the development of cirrhosis complications, ΔSMI/yr% was independently associated, even after adjusting for the Child-Pugh and model for end stage liver disease (MELD)-Na scores. In addition, ΔSMI/yr% showed a good predictive performance for the development of cirrhosis complications within 6 months after 1-year follow-up in all subgroups, with a cut-off of -2.62 (sensitivity, 83.9%; specificity, 74.5%) in the overall population. SMI at 1-year and Child-Pugh score were independent factors associated with survival. In addition, changes in sarcopenia status significantly stratified survival. Conclusions: ΔSMI/yr% was a good predictor of the development of cirrhosis complications in outpatients with cirrhosis, independent of Child-Pugh and MELD scores.
Abstract
Background/Aims: Sarcopenia negatively affects the prognosis of cirrhotic patients, but clinical implications of changes in muscle mass remain unclear. We aimed to elucidate its role in the prognosis of outpatients with cirrhosis. Methods: Patients with cirrhosis who underwent annual abdominal computed tomography (CT) for hepatocellular carcinoma surveillance were included in the prospective cohort. The L3 skeletal muscle index (SMI) was adopted as a proxy for the amount of skeletal muscle, and the rate of SMI change between inclusion and after 1 year (ΔSMI/yr%) was calculated. Results: In total, 595 patients underwent a second CT after 1 year. Among them, 109 and 64 patients had sarcopenia and Child-Pugh class B/C decompensation at inclusion, which changed to 103 and 45 at the 1-year follow-up, respectively. During a median follow-up of 30.1 months after 1 year, 86 patients had at least one cirrhosis complication, and 18 died or received liver transplantation. In the development of cirrhosis complications, ΔSMI/yr% was independently associated, even after adjusting for the Child-Pugh and model for end stage liver disease (MELD)-Na scores. In addition, ΔSMI/yr% showed a good predictive performance for the development of cirrhosis complications within 6 months after 1-year follow-up in all subgroups, with a cut-off of -2.62 (sensitivity, 83.9%; specificity, 74.5%) in the overall population. SMI at 1-year and Child-Pugh score were independent factors associated with survival. In addition, changes in sarcopenia status significantly stratified survival. Conclusions: ΔSMI/yr% was a good predictor of the development of cirrhosis complications in outpatients with cirrhosis, independent of Child-Pugh and MELD scores.
참고문헌 (34)
- Lai JC, "Malnutrition, frailty, and sarcopenia in patients with cirrhosis : 2021 practice guidance by the American Association for the Study of Liver Diseases", Hepatology, 74, pp.1611~1644 (2021)
- Sugimoto K, "Hyperglycemia in non-obese patients with type 2 diabetes is associated with low muscle mass : the multicenter study for clarifying evidence for sarcopenia in patients with diabetes mellitus", J Diabetes Investig, 10, pp.1471~1479 (2019)
- Sabatino A, "Sarcopenia in chronic kidney disease : what have we learned so far?", J Nephrol, 34, pp.1347~1372 (2021)
- Nipp RD, "Sarcopenia is associated with quality of life and depression in patients with advanced cancer", Oncologist, 23, pp.97~104 (2018)
- Nishikawa H, "Japan Society of Hepatology guidelines for sarcopenia in liver disease(1st edition) : recommendation from the working group for creation of sarcopenia assessment criteria", Hepatol Res, 46, pp.951~963 (2016)
- European Association for the Study of the Liver, "EASL clinical practice guidelines on nutrition in chronic liver disease", J Hepatol, 70, pp.172~193 (2019)
- Ankur Jindal, "Sarcopenia: Ammonia metabolism and hepatic encephalopathy", Clinical and Molecular Hepatology, 25(3), pp.270~279 (2019), 대한간학회
- Tantai X, "Effect of sarcopenia on survival in patients with cirrhosis : a meta-analysis", J Hepatol, 76, pp.588~599 (2022)
- Merion RM, "Longitudinal assessment of mortality risk among candidates for liver transplantation", Liver Transpl, 9, pp.12~18 (2003)
- Huo TI, "Evaluation of the increase in model for end-stage liver disease(DeltaMELD)score over time as a prognostic predictor in patients with advanced cirrhosis : risk factor analysis and comparison with initial MELD and Child-Turcotte-Pugh score", J Hepatol, 42, pp.826~832 (2005)
- Brock GN, "Use of rapid model for endstage liver disease(MELD)increases for liver transplant registrant prioritization after MELD-Na and Share 35, an evaluation using data from the United Network for Organ Sharing", PLoS One, 14, pp.e0223053~ (2019)
- Hanai T, "Rapid skeletal muscle wasting predicts worse survival in patients with liver cirrhosis", Hepatol Res, 46, pp.743~751 (2016)
- 정재윤, "Presence of Sarcopenia and Its Rate of Change Are Independently Associated with Long-term Mortality in Patients with Liver Cirrhosis", Journal of Korean Medical Science, 33(50), pp.1~13 (2018), 대한의학회
- Salinas-Miranda E, "Prognostic value of early changes in CT-measured body composition in patients receiving chemotherapy for unresectable pancreatic cancer", Eur Radiol, 31, pp.8662~8670 (2021)
- Nakashima Y, "Skeletal muscle loss after esophagectomy is an independent risk factor for patients with esophageal cancer", Ann Surg Oncol, 27, pp.492~498 (2020)
- Korean Liver Cancer Association (KLCA) and National Cancer Center (NCC, "2018 Korean Liver Cancer Association–National Cancer Center Korea Practice Guidelines for the Management of Hepatocellular Carcinoma", Gut and Liver, 13(3), pp.227~299 (2019), 거트앤리버 소화기연관학회협의회[DOI]
- Jihye Kim, "Substantial risk of recurrence even after 5 recurrence-free years in early-stage hepatocellular carcinoma patients", Clinical and Molecular Hepatology, 26(4), pp.516~528 (2020), 대한간학회[DOI]
- Mitsiopoulos N, "Cadaver validation of skeletal muscle measurement by magnetic resonance imaging and computerized tomography", J Appl Physiol(1985), 85, pp.115~122 (1998)
- Salvatore Piano, "Changes in the epidemiology and management of bacterial infections in cirrhosis", Clinical and Molecular Hepatology, 27(3), pp.437~445 (2021), 대한간학회[DOI]
- Cosmas Rinaldi Adithya Lesmana, "Managing liver cirrhotic complications: Overview of esophageal and gastric varices", Clinical and Molecular Hepatology, 26(4), pp.444~460 (2020), 대한간학회
- The Korean Association for the Study of the Liver, "2017 KASL clinical practice guidelines management of hepatitis C: Treatment of chronic hepatitis C", Clinical and Molecular Hepatology, 24(3), pp.230~277 (2018), 대한간학회
- The Korean Association for the Study of the Liver, "KASL clinical practice guidelines for liver cirrhosis: Varices, hepatic encephalopathy, and related complications", Clinical and Molecular Hepatology, 26(2), pp.83~127 (2020), 대한간학회[DOI]
- Levey AS, "Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate", Ann Intern Med, 145, pp.247~254 (2006)
- Putter H, "On the relation between the cause-specific hazard and the subdistribution rate for competing risks data : the Fine-Gray model revisited", Biom J, 62, pp.790~807 (2020)
- Kim TH, "Determinants of re-compensation in patients with hepatitis B virusrelated decompensated cirrhosis starting antiviral therapy", Aliment Pharmacol Ther, 55, pp.83~96 (2022)
- Hyung Joon Yim, "Comparison of clinical practice guidelines for the management of chronic hepatitis B: When to start, when to change, and when to stop", Clinical and Molecular Hepatology, 26(4), pp.411~429 (2020), 대한간학회[DOI]
- Omar Alshuwaykh, "Current and future strategies for the treatment of chronic hepatitis C", Clinical and Molecular Hepatology, 27(2), pp.246~256 (2021), 대한간학회[DOI]
- Carey EJ, "A multicenter study to define sarcopenia in patients with end-stage liver disease", Liver Transpl, 23, pp.625~633 (2017)
- Kang SH, "Impact of sarcopenia on prognostic value of cirrhosis : going beyond the hepatic venous pressure gradient and MELD score", J Cachexia Sarcopenia Muscle, 9, pp.860~870 (2018)
- Mauro E, "Cystatin C and sarcopenia predict acute on chronic liver failure development and mortality in patients on the liver transplant waiting list", Transplantation, 104, pp.e188~e198 (2020)
- Zeng X, "Sarcopenia as a prognostic predictor of liver cirrhosis : a multicentre study in China", J Cachexia Sarcopenia Muscle, 12, pp.1948~1958 (2021)
- Mauro E, "Sarcopenia HIBA score predicts sarcopenia and mortality in patients on the liver transplant waiting list", Hepatol Commun, 6, pp.1699~1710 (2022)
- Kanghyug Choi, "The association of the serum levels of myostatin, follistatin, and interleukin-6 with sarcopenia, and their impacts on survival in patients with hepatocellular carcinoma", Clinical and Molecular Hepatology, 26(4), pp.492~505 (2020), 대한간학회[DOI]
- Aamann L, "Resistance training increases muscle strength and muscle size in patients with liver cirrhosis", Clin Gastroenterol Hepatol, 18, pp.1179~1187 (2020)